Avaleht › Müeloom › Florida › Miami
Müeloom kliinilised uuringud linnas Miami, FL
21 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas Miami ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
VärbamineFaas 1/2
- University of Miami, Miami
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
VärbamineFaas 2
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- University of Miami/Sylvester Cancer Institute - Alex's Place, Miami
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building, Miami
- ja veel 2
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
VärbamineFaas 2
- University of Miami, Miami
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
VärbamineFaas 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 2
- Miami Cancer Institute at Baptist Health, Inc., Miami
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
VärbamineFaas 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
- ja veel 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
VärbamineFaas 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center - Kendall, Miami
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
VärbamineFaas 2
- University of Miami, Miami
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
VärbamineFaas 1
- University of Miami Don Soffer Clinical Research Center, Miami
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
VärbamineFaas 1/2
- Research Site, Miami
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
VärbamineFaas 1
- University of Miami, Miami
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
VärbamineFaas 4
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Värbamine
- University of Miami, Miami
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
VärbamineVaatlusuuring
- University of Miami Hospitals, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
VärbamineFaas 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
VärbamineFaas 2
- University of Miami, Miami
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
VärbamineFaas 2
- University of Miami, Miami
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
VärbamineFaas 2
- University of Miami, Sylvester Comprehensive Cancer Center, Miami
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
- Miami Cancer Institute, Miami
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
VärbamineFaas 2
- University of Miami, Miami
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
VärbamineFaas 1
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Durham, NC37 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
Muud uuringud linnas Miami
- Rinnavähk42 uuringut
- Vähk (kõik liigid)36 uuringut
- Mitteväikerakuline kopsuvähk31 uuringut
- Eesnäärmevähk27 uuringut
- Rasvumine27 uuringut
- Äge müeloidne leukeemia24 uuringut
- Metastaatiline vähk24 uuringut
- Munasarjavähk23 uuringut
- Ülekaalulisus23 uuringut
- Haavandiline koliit21 uuringut
- Alzheimeri tõbi20 uuringut
- Kopsuvähk20 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.